Compare AbCellera Biologics Inc (ABCL) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Raymond James Financial, Inc. — how do they compare? AbCellera Biologics Inc trades at $10 (market cap $2.99B), while Raymond James Financial, Inc. trades at $179.92 (market cap $34.63B). The key difference: Raymond James Financial, Inc. is far larger — about 11.6× AbCellera Biologics Inc's market cap, and Raymond James Financial, Inc. pays a 1.2% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | RJF | |
|---|---|---|
Market Cap | $2.99B | $34.63B |
Sector | Health | Financials |
52-Week High | $9.76 | $180.55 |
52-Week Low | $2.78 | $140.89 |
Enterprise Value | $2.58B | — |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
Raymond James Financial (RJF) trades at $179.09, up 1.43% today, with a bullish technical signal and strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows consistent revenue growth, reaching $13.84B in 2025, and a solid net income margin of 15.37%. Recent news highlights record Q3 2026 revenues and strategic acquisitions as key growth drivers.
The outlook is positive with a consensus price target of $183.75, though risks include market volatility and execution of growth initiatives. The stock presents an opportunity based on fundamental strength and analyst support, balanced by the need to monitor expense management and economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
